Breakthrough drug trial aims to halt rare eye disease progression
NCT ID NCT07419334
Summary
This study is testing whether the drug ALK-001 can safely slow down the progression of Stargardt disease, a rare genetic condition that causes vision loss. It will involve 230 participants aged 8 to 45 who have been diagnosed with the disease. Participants will be randomly assigned to receive either the active drug or a placebo for two years to see if the treatment reduces the growth of damaging lesions in the eye.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STARGARDT DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.